GILD · News · 20260815N
Licensing / Collaboration Deals
GILEAD SCIENCES, INC. · 2026-08-15 · Importance 34 · Surprise 42 · In source text
Gilead paid MacroGenics a $10 million milestone after exercising an option to license a preclinical bispecific program. The transaction expands Gilead’s oncology pipeline through the companies’ 2022 collaboration and supports MacroGenics’ TRIDENT platform. The program remains preclinical, so additional development and clinical milestones will determine its longer-term strategic and financial impact.
Key facts
- Gilead Sciences exercised an option to license a preclinical bispecific program and paid MacroGenics a $10 million milestone payment. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | realized | -0.0% | Gilead Sciences exercised an option to license a preclinical bispecific program and paid MacroGenics a $10 million milestone payment. |